Walmart recalls shrimp possibly exposed to radioactive material
The US Food and Drug Administration said varieties of frozen shrimp sold under Walmart's Great Value label could have been exposed to a dangerous isotope in shipping containers.
One sample of breaded shrimp tested positive for the substance, but this positive sample "did not enter US commerce", the FDA said.
Consumers are advised to throw away recently bought Walmart shrimp that matches this description - and not to eat or serve it.
"The health and safety of our customers is always a top priority," a Walmart spokesperson told the BBC. "We have issued a sales restriction and removed this product from our impacted stores. We are working with the supplier to investigate."
The spokesperson added that consumers who bought the recalled products can visit any Walmart location for a full refund.
The recalled shrimp was sold at Walmart locations in Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia, and shoppers in those states were advised to be cautious.
It came from an Indonesian supplier that has since had a number of shipping containers denied entry to the US, the FDA said.
One shipment tested positive for Cesium-137, the radioactive form of the chemical element Cesium.
The amount contained in the tested shipment held by the FDA was not enough to pose acute harm to consumers, but exposure over time could pose an elevated risk of cancer by damaging living cells in the body, said officials from the agency.
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
27 minutes ago
- Business Wire
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse
NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Evolysse ™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume. 'This submission represents an important milestone in expanding our Evolysse ™ collection of injectable HA gels,' said Dr. Rui Avelar, MD, Chief Medical Officer and Head of R&D. 'Sculpt is our most structured product, manufactured using a novel technology and designed to address mid-face volume loss, a high-value segment in facial aesthetics.' Evolus anticipates that the FDA's review will follow the standard PMA process, with approval expected in the second half of 2026. The submission underscores Evolus' commitment to bringing its collection of injectable hyaluronic acid gel products to market and its readiness to meet rigorous regulatory requirements. In support of the PMA application, a U.S. pivotal study which evaluated the safety and effectiveness of the product in a multicenter, double-blinded, controlled, non-inferiority designed trial was conducted. Patients were followed for 24 months from initial treatment. A total of 304 patients were enrolled and randomized to receive Evolysse ™ Sculpt or Restylane ® -Lyft. The Evolysse ™ Sculpt injectable HA gel product is expected to be the flagship brand in the Evolysse ™ collection. Designed by Symatese using innovative Cold-X ™ technology, which helps preserve the natural structure of the HA molecule for long-lasting, natural-looking results, Sculpt will enter the highest value segment for today's dermal filler market and be among the few products currently indicated for the mid-face area. About Evolus, Inc. Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau ® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse ™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at and follow us on LinkedIn, X, Instagram or Facebook. Forward-Looking Statements This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, including statements about future events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical or current facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would' or the negative of those terms, or other comparable terms intended to identify statements about the future. The company's forward-looking statements include, but are not limited to, statements related to anticipated product launches and the timing of regulatory submissions and approvals. The forward-looking statements included herein are based on our current expectations, assumptions, estimates and projections, which we believe to be reasonable, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control, include, but are not limited to, uncertainties associated with our ability to comply with the terms and conditions in the Medytox Settlement Agreements, our ability to fund our future operations or obtain financing to fund our operations, unfavorable global economic conditions and the impact on consumer discretionary spending, uncertainties related to customer and consumer adoption of Jeuveau ® and Evolysse ™, the efficiency and operability of our digital platform, competition and market dynamics, our ability to successfully launch and commercialize our products in new markets, including the Evolysse ™ dermal filler product line in the U.S., our ability to maintain regulatory approvals of Jeuveau ® or obtain regulatory approvals for new product candidates or indications, our reliance on Symatese to achieve regulatory approval for the Evolysse ™ dermal filler product line in the U.S., and other risks described in our filings with the Securities and Exchange Commission, including in the section entitled 'Risk Factors' in our Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed with the Securities and Exchange Commission on August 5, 2025. These filings can be accessed online at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events. If we do update or revise one or more of these statements, investors and others should not conclude that we will make additional updates or corrections. Jeuveau ® and Nuceiva ®, are registered trademarks and Evolysse ™ is a trademark of Evolus, Inc. Hi-Pure ™ is a trademark of Daewoong Pharmaceutical Co, Ltd. Cold-X ™ and Estyme ® are trademarks of Symatese Group and Symatese Aesthetics S.A.S. Restylane ® is a trademark of Galderma S.A.
Business Wire
27 minutes ago
- Business Wire
Nucleus RadioPharma Appoints Former FDA Commissioner Dr. Stephen Hahn as CEO to Scale Patient Access to Radiopharmaceutical Therapies
ROCHESTER, Minn.--(BUSINESS WIRE)-- Nucleus RadioPharma, a next-generation contract development and manufacturing organization (CDMO) specializing in radiopharmaceuticals, today announced the appointment of Dr. Stephen M. Hahn as chief executive officer. Hahn's leadership signals Nucleus RadioPharma's urgency in scaling the infrastructure necessary to make minimally invasive, targeted cancer therapies accessible to patients around the world. Hahn joins Nucleus RadioPharma after serving as CEO-partner of Flagship Pioneering and CEO of Harbinger Health since 2021. He served as the 24th U.S. Food and Drug Administration (FDA) commissioner from 2019 to 2021, overseeing both COVID and non-COVID regulatory affairs. Before joining the FDA, he was the chief medical executive at MD Anderson Cancer Center in Houston. The combination of regulatory, clinical and operational knowledge gives him deep insight into how therapies move from clinic to patient. Radiopharmaceuticals represent one of the most promising frontiers in oncology, offering treatments that are less toxic, less invasive and far more precise in targeting cancer cells. When patients receive these therapies, outcomes improve and quality of life is preserved. However, widespread access to radiopharmaceuticals remains extremely limited, not due to scientific barriers, but logistical ones. Three interdependent issues drive these supply chain challenges: a fragile and insufficient supply of key isotopes, limited GMP-compliant infrastructure capable of handling a range of medical isotopes and an underdeveloped operational capacity to manage radioactive drugs. 'Radiopharmaceuticals are the next frontier of precision oncology care,' said Hahn. 'But without the infrastructure to deliver these treatments, their impact is fundamentally limited. At Nucleus RadioPharma, we have an extraordinary team that is committed to breaking those barriers. Together, we will scale the systems and infrastructure needed to make these lifesaving therapies available to all who need them.' Under Hahn's leadership, Nucleus RadioPharma is uniquely positioned to tackle these issues, take radiopharmaceuticals to new levels of precision and efficacy and make minimally invasive therapies the new standard for cancer treatment. 'Steve's experience as both a physician treating patients and as a leader at the FDA brings an unparalleled perspective to Nucleus as the company works to build the infrastructure needed to accelerate the widespread availability of radiopharmaceuticals,' said Justin Butler, partner at Eclipse and Nucleus board member. 'His new role is a major indicator to the oncology community that radiopharmaceuticals are the future of precision cancer treatment, and that Nucleus is poised to lead the next era.' Founded in 2022 through a collaboration between Eclipse and Mayo Clinic, Nucleus has raised $72 million in funding to date, including participation from AstraZeneca. The company is building a network of advanced facilities, starting in Mesa, Arizona, and Spring House, Pennsylvania, that integrate research, development and commercial-scale production under one roof, enabling faster, more reliable distribution to clinical trial sites and treatment centers. 'With one of the largest cancer theranostics practices in the world, we have a responsibility to drive continual innovation and develop new targeted diagnostic and therapeutic radioisotopes for our patients,' said Dr. Cheryl Willman, Stephen and Barbara Slaggie executive director for Mayo Clinic Cancer Programs and Mayo Clinic Comprehensive Cancer Center. 'With Steve's exemplary leadership skills and expertise as a cancer physician and scientist, our future could not be brighter.' In his first year as CEO, Hahn will focus on completing the company's GMP readiness at its Rochester, Minnesota, facility, expanding R&D capabilities, launching Nucleus' data platform and forging strategic partnerships. Over the next five years, the company aims to dramatically increase manufacturing capacity and advance initiatives that improve patient access worldwide. For more information on Nucleus RadioPharma, see here. Nucleus RadioPharma is an innovative CDMO dedicated to the development and manufacturing of targeted radiotherapies. With an emphasis on innovation and quality, Nucleus provides an array of services, from formulation and analytical development to regulatory documentation and drug product manufacturing. Its technology platforms are at the forefront of radiopharmaceutical research, designed to advance new therapies through clinical trials to commercialization. Learn more at
Medscape
27 minutes ago
- Medscape
Managing Primary Care of Patients After Cancer Treatment
The good news about cancer is that there are increasing numbers of people who are surviving after treatment, in some cases due to newer medicines and, in others, due to screening detecting the disease earlier. As of January 1, about 18.6 million people in the US had a history of oncologic treatment, a figure expected to exceed 22 million by 2035, researchers at the American Cancer Society estimated in a new report. While the estimate excludes most in situ carcinoma and basal cell or squamous cell skin cancers, it still shows how primary care clinicians will likely face increasing demands to help patients manage the aftermath of their cancer treatment. Some cancers appear to be showing up more in younger people, perhaps in part due to sedentary lifestyles and poor diet. Research found excess body weight may play a role in global increases seen in early-onset breast, pancreatic, colorectal, and kidney cancers. And treatments for cancer have been undergoing radical changes. Older chemotherapies that stop fast-growing cells, such as cancerous ones, remain widely used, but many new kinds of drugs have been introduced, sometimes only with emerging data available on their safety and benefits. These include immune checkpoint inhibitors, chimeric antigen receptor T-cell therapies, and new forms of monoclonal antibodies. 'It's an exploding field' of treatments, said Kimberly S. Peairs, MD, the vice chair for clinical affairs at Johns Hopkins School of Medicine, Baltimore. Yet there has not been much focus in US medicine in general on what happens when patients cycle back to being seen primarily by their primary care clinicians after treatment. Peairs in 2015 founded the Primary Care for Cancer Survivors Program , which has served as a model for physicians elsewhere seeking to help bridge gaps that might otherwise happen in patient care. For example, Ilana Yurkiewicz, MD, of Stanford University School of Medicine sought advice from Peairs when she sought to create a more unified approach to caring for patients who have had cancer treatments. Yurkiewicz has worked closely with Natasha Steele, MD, a Stanford colleague who is a former lymphoma patient. In an interview with Medscape Medical News , Steele noted how patients can face a jarring change at the end of treatment. They transition from relying heavily on oncologists' expertise during their life-threatening illness to needing to resume participation in managing aspects of their own care. 'During cancer treatment, patients have to put their lives in the hands of their oncologists and trust they are safe,' Steele said. 'But survivorship is a paradigm shift where we're really trying to empower patients with information and skills to manage some of their health risks longitudinally, and this can be challenging for a lot of reasons.' For primary care clinicians, the changes in treatment and outcomes are allowing them to participate in one of the most rapidly advancing fields of medicine. For example, the National Comprehensive Cancer Network (NCCN) updated its guidelines 241 times last year. Clinicians in primary care can also rely on many tools like UptoDate and continuing medical education courses to aid with this challenge. Physicians can help patients adjust to their 'new normal' life after cancer treatment, Peairs said. 'We're not asking primary care people to be oncologists,' she said. Below are three tips for primary care clinicians based on interviews with physicians who have significant expertise in oncology and in the emerging field known as survivorship. 1. Try reaching your patients about steps to prevent recurrence or future cancers. Primary care clinicians can help get important messages through to patients who may struggle to keep track of follow-up care, said Kathleen N. Mueller, MD, the system director for integrative medicine and cancer survivorship for Nuvance Health, a seven-hospital health system in Connecticut and southeastern New York. Muller also serves on the board of directors of the American Academy of Family Physicians. 'When you're undergoing treatment for cancer, it's really difficult to process information,' Mueller said. 'It is an overwhelming diagnosis.' In many cases, people did not suspect they had cancer before their diagnosis. 'Now, all of a sudden, they're thinking about their mortality,' she said. 'They may not get all the information that's communicated to them. So they might miss the fact that they're supposed to get, for example, a mammogram every 6 months with an MRI.' A key to success with these talks about preventing recurrence is finding a way to make sure patients hear the message, such as by discussing different steps at different visits, said Crystal S. Denlinger, MD, the chief executive officer of NCCN. 'It's less about having an exact knowledge and more about knowing where to go to get the knowledge you need,' Denlinger said. 'You don't need to tackle it all at every visit. During one visit, you could ask somebody about how physically active they are and then talk about the fact that physical activity can lower the rate of development of cancer, and for certain cancers, could actually lower the rate of recurrence.' Another visit could be an opportunity to discuss nutrition. 'Maybe you ask them about their diet and how much processed food they're eating, how many fruits and vegetables they're eating,' Denlinger said. 'You don't have to tackle the whole mountain. Start with a few steps.' Denlinger also said it's important to acknowledge the good habits patients already have, such as getting enough physical activity. 2. Provide patients opportunities to discuss how they are feeling. Steele said she works to provide a 'safe space' where patients can talk about what they are going through. 'After cancer treatment, a lot of people don't feel like the person they were before cancer,' Steele said, adding that this can be distressing for them. 'The way I approach this with my patients is I try to normalize the challenges and the trauma of cancer and give them the skills to figure out how to use parts of the experience in a meaningful way,' she said. Primary care clinicians have a chief role in helping patients with concerns about recurrence and the challenges of managing life after cancer treatment, Denlinger said. Anxiety is likely to crop up 'in those quiet moments' after the most challenging phases of cancer treatment are done, Denlinger said. After diagnosis, patients often shift into a 'I've got to fight the cancer' mindset, needed to help them focus and get through treatments. The demands of cancer care, along with the attendant disruptions to home and family life, can provide some degree of distraction. After treatment, patients disconnect with their constant oncology engagement, she said. 'Now they're returning back to the life that they had before they had cancer,' Denlinger said. 'This may be a time where primary care providers are an important resource to address some of this post-treatment anxiety, as they're sort of processing all the things that they've been through. Fear of recurrence is real, and it needs to continue to be assessed.' Peairs and her colleagues at Johns Hopkins published a 2020 paper about the first 4 years of the Johns Hopkins Primary Care for Cancer Survivors Program. This paper included results from a survey of patients that found many sought help with emotional needs. These included fear of recurrence, reported by 64.2%; the challenge of living with uncertainty, 62.5%; and managing difficult emotions: anger, anxiety, and depression (53.1%). People may also have concerns about what their diagnosis means for their family members, Mueller said. For example, a woman diagnosed with breast cancer may be worried about her daughter's risk. Family physicians often build relationships with their patients over many years, and in many cases, know something about their relatives, giving them insights that oncologists couldn't be expected to have, Mueller said. 'It's the longitudinal, consistent relationship that we have,' she said. 3. Be aware that a patient's risk can change over time. It's important to check for changes in both your patients' family history and the guidelines for screening, Denlinger said. For example, a history done several years ago may not reflect recent diagnoses of cancer in a patient's family. There also are newer genetic tests, such as those for pancreatic cancer risks, that may be suitable for patients, she said.
